
price close busi octob
hub precis medicin
domin global leader next gener sequenc
instrument consum
biomed devic servic
solid beat guid light reiter
hold pt
deliv top bottom line beat primarili relat third-parti payment
mostli relat new ivd test kit partnership announc
octob howev guid street primarili relat transitori
effect nextseq custom upgrad novaseq miseq custom migrat
nextseq dx result paus sequenc upgrad process
expect sequenc consum grow low teen year
prior guid mid-teen also increas concern relat acquir
see admir busi prone lumpi quarter
custom transit instrument life cycl shift requir strong global fund
think could prove challeng next year appear china
rais ep estim reiter hold rais pt
result rev y/i beat
primarili driven beat vs model services/oth relat ivd
licens agreement mostli adapt small adj ep
y/i beat our/street primarili due revenu margin beat
collabor payment adj gm beat adj om
beat guid adj gm q/q due revenue mix
guid flow beat rais adj ep
prior despit revenu beat reiter
revenue growth guid impli revenue growth guid
prior impli guid contempl on-going slowdown array
expect declin lower sequenc consum growth larg
relat transitori sequenc swap impact discuss
pacbio deal today uk competit market author announc
provision found ilmn propos acquisit may expect result
substanti lessen competit suppli system short-
read long-read uk structur remedi identifi
potenti effect would block merger base understand
provision found actual like substanti lessen competit
slc last year deviat case time
provision find deal spread widen sinc
call appear unlik close view
spread joy move think part relat grow uncertainti
close announc week ago hire joydeep goswami role
svp corpor develop strateg plan move applaud see
page addit jay flatley transit execut chairman chairman
reduc day-to-day management-typ involv compani
ancestri spark rebound dtc remain cautiou intrigu
new ancestryhealth offer launch earli understand
sequenc suppli ancestri sequenc
consum offer ngs-base surmis exom offer consum
appear upgrad array genotyp offer view
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
pt rais pt use multipl
new adj ep estim rais
move sidelin last quarter dont believ ultra-premium
multipl justifi compani look grow top line year
busi lumpi vulner larg miss said model
top line growth what lack visibl
growth rate given wide rang move part would look get construct
concern prove transitori announc genom price
point would meaning acceler top line add headwind
gross oper net incom margin work hard drive cost
sequenc abl usher eagerli await genom think
potenti game-chang sequenc meaning move clinic
global popul genom project prior pre-announc result
investor concern compani guid revenu ramp
vs popul genom initi turn concern
appropri said encourag uk move ahead uk
biobank initi sequenc genom think may take year
complet recent ndr meet indic good line sight
global program track would account
ramp peg sampl us million veteran
program genom england phase franc australia singapor four
project manag indic fund issu matter get
sign variou constitu stakehold also indic even
us us initi move along slowli compani previous
expect though expect ramp nice said us-bas popul
sequenc project move along slowli expect lack visibl
governments/stakehold ous/emerg countri abl move faster
us deal highli complex requir care planning/design patient
welcom joydeep goswami fortifi potenti capit deploy
initi move think part relat grow uncertainti close
announc week ago hire joydeep goswami role svp
corpor develop strateg plan move applaud joydeep report
directli ceo franci desouza join thermo fisher serv
presid thermo oncolog unit previous serv leadership role
invitrogen serv presid asia pacif japan
thermo fisher creat stem cell regen medicin busi
invitrogen work mckinsey strategi consult pharmaceut
medic technolog technolog compani mr goswami hold ph
chemic engin massachusett institut technolog
bachelor degre chemic engin indian institut technolog
dtc troubl array consum declin y/i microarray servic
 declin y/i reflect on-going weak relat lower volum
consum genet test meanwhil lower guidanc array
y/i y/i call illumina ceo franci desouza
indic expect dtc reacceler come year us doesnt
impli recoveri lower convict abil dtc genet
test busi rev bounc back within next year two perhap
china concern china revenu declin
y/i grow concern return growth china
given trade war concern possibl competit concern bgi
cite growth china relat reproduct health nipt oncolog cite
reduct research revenu china also indic research fund
china y/i believ bgi rel low threat competit
unit state concern possibl could win one
larg popul genom project away
hold unchang target price octob
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
hold unchang target price octob
biomed devic servic
hold unchang target price octob
biomed devic servic
hold unchang target price octob
biomed devic servic
hold unchang target price octob
biomed devic servic
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research iii best author analyst
knowledg she/h receipt materi non-publ inform issuer
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin octob et
date time product octob et
pt use multipl adj ep estim
pt use multipl adj ep estim y/i
risk achiev target price valuat
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
hold unchang target price octob
biomed devic servic
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
